IMC Chicago’s TG Therapeutics TGTX Stock Holding History

IMC Chicago’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,903	Closed	-$748K	–	4422
2025 Q3	$827K	Sell	22,903 -4,952	-18%	-$163K	﹤0.01%	2842
2025 Q2	$1M	Buy	+27,855	New	+$1.04M	﹤0.01%	2479
2024 Q4	–	Sell	-15,698	Closed	-$451K	–	3338
2024 Q3	$367K	Buy	+15,698	New	+$343K	﹤0.01%	2555
2024 Q1	–	Sell	-18,970	Closed	-$302K	–	2507
2023 Q4	$324K	Buy	+18,970	New	+$220K	﹤0.01%	1732

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

IMC Chicago's TGTX Position: Q4 2025 in Review

IMC Chicago sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 22,903 shares — an estimated $748K sold.

IMC Chicago first reported a position in TGTX in Q4 2023 and held it in 4 quarters. The position peaked at $1M in Q2 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

IMC Chicago reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
IMC Chicago sold 22,903 TG Therapeutics shares in Q4 2025, an estimated $748K.
IMC Chicago first reported a position in TG Therapeutics in Q4 2023 and held it in 4 quarters.
IMC Chicago's TG Therapeutics position peaked at $1M in Q2 2025.
351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on IMC Chicago's 13F filing for Q4 2025, filed 29 Jan 2026.